Amylyx Pharmaceuticals (AMLX) Current Assets (2021 - 2026)

Amylyx Pharmaceuticals' Current Assets history runs 6 years deep, the most recent figure standing at $285.0 million for Q1 2026.

• In Q1 2026, Current Assets rose 31.87% year-over-year to $285.0 million; the TTM figure through Mar 2026 stood at $285.0 million (up 31.87% YoY), while the FY2025 annual figure was $323.7 million, up 70.86% from the prior year.
• Current Assets was $285.0 million for Q1 2026 at Amylyx Pharmaceuticals, down from $323.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $464.7 million in Q4 2023 to a low of $172.2 million in Q3 2022.
• Historically, Current Assets has averaged $311.1 million across 5 years, with a median of $323.7 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Current Assets jumped 264.11% in 2022, then slumped 59.23% in 2024.
• A 5-year view of Current Assets shows it stood at $382.1 million in 2022, then grew by 21.6% to $464.7 million in 2023, then plunged by 59.23% to $189.4 million in 2024, then surged by 70.86% to $323.7 million in 2025, then slipped by 11.94% to $285.0 million in 2026.
• The last three Current Assets figures came in at $285.0 million (Q1 2026), $323.7 million (Q4 2025), and $353.4 million (Q3 2025), per Business Quant data.